bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure from Omission of Upfront Craniospinal Irradiation in Patients with Low-Risk WNT-Pathway Medulloblastoma Is Associated with Unacceptably High Risk of Neuraxial Failure
Authors: Gupta Tejpal , Pervez Shizan , Dasgupta Archya , Chatterjee Abhishek , Epari Sridhar , Chinnaswamy Girish , Jalali Rakesh
Published: April 2023

Supplementary Figure from Omission of Upfront Craniospinal Irradiation in Patients with Low-Risk WNT-Pathway Medulloblastoma Is Associated with Unacceptably High Risk of Neuraxial Failure
Supplementary Figure S4 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
Authors: Serra-Camprubí Queralt , Verdaguer Helena , Oliveros Winona , Lupión-Garcia Núria , Llop-Guevara Alba , Molina Cristina , Vila-Casadesús Maria , Turpin Anthony , Neuzillet Cindy , Frigola Joan , Querol Jessica , Yáñez-Bartolomé Mariana , Castet Florian , Fabregat-Franco Carles , Escudero-Iriarte Carmen , Escorihuela Marta , Arenas Enrique J. , Bernadó-Morales Cristina , Haro Noemí , Giles Francis J. , Pozo Óscar J. , Miquel Josep M. , Nuciforo Paolo G. , Vivancos Ana , Melé Marta , Serra Violeta , Arribas Joaquín , Tabernero Josep , Peiró Sandra , Macarulla Teresa , Tian Tian V.
Published: April 2023

Growth of cells derived from CCA_PDXs in the 3D ex vivo culture system. (A) Representative bright-field images of cells derived from indicated CCA_PDXs and cultured ex vivo. Images are from days 0, 3, 7, and 10. Scale bar, 1 mm.
Supplementary Figure S2 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
Authors: Serra-Camprubí Queralt , Verdaguer Helena , Oliveros Winona , Lupión-Garcia Núria , Llop-Guevara Alba , Molina Cristina , Vila-Casadesús Maria , Turpin Anthony , Neuzillet Cindy , Frigola Joan , Querol Jessica , Yáñez-Bartolomé Mariana , Castet Florian , Fabregat-Franco Carles , Escudero-Iriarte Carmen , Escorihuela Marta , Arenas Enrique J. , Bernadó-Morales Cristina , Haro Noemí , Giles Francis J. , Pozo Óscar J. , Miquel Josep M. , Nuciforo Paolo G. , Vivancos Ana , Melé Marta , Serra Violeta , Arribas Joaquín , Tabernero Josep , Peiró Sandra , Macarulla Teresa , Tian Tian V.
Published: April 2023

Histopathologic characterization of CCA_PDXs. (A) Histologic and immunohistochemical images of CCA_PDXs. H&E staining, and immunohistochemical staining of KRT19 (CCA marker) and HepPar1 (HCC marker) were shown. CCA_PDX samples were collected at passage 1 (PDX41, PDX96, PDX118, PDX123, PDX132, and PDX133) or passage 2 (PDX58, PDX62, PDX67, PDX68.2, PDX75, PDX75.2, PDX78, PDX84, PDX85, PDX104, PDX119, and PDX120). Scale bar, 250 µm.
Table S1 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
Authors: Kabraji Sheheryar , Ni Jing , Sammons Sarah , Li Tianyu , Van Swearingen Amanda E.D. , Wang Yanzhi , Pereslete Alyssa , Hsu Liangge , DiPiro Pamela J. , Lascola Chris , Moore Heather , Hughes Melissa , Raghavendra Akshara S. , Gule-Monroe Maria , Murthy Rashmi K. , Winer Eric P. , Anders Carey K. , Zhao Jean J. , Lin Nancy U.
Published: April 2023

Characteristics of patients with both CNS and extracranial response
Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
Authors: Kabraji Sheheryar , Ni Jing , Sammons Sarah , Li Tianyu , Van Swearingen Amanda E.D. , Wang Yanzhi , Pereslete Alyssa , Hsu Liangge , DiPiro Pamela J. , Lascola Chris , Moore Heather , Hughes Melissa , Raghavendra Akshara S. , Gule-Monroe Maria , Murthy Rashmi K. , Winer Eric P. , Anders Carey K. , Zhao Jean J. , Lin Nancy U.
Published: April 2023

Figures S1 and S2
Supplementary Table S1-S3 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
Authors: Milewski David , Jung Hyun , Brown G. Thomas , Liu Yanling , Somerville Ben , Lisle Curtis , Ladanyi Marc , Rudzinski Erin R. , Choo-Wosoba Hyoyoung , Barkauskas Donald A. , Lo Tammy , Hall David , Linardic Corinne M. , Wei Jun S. , Chou Hsien-Chao , Skapek Stephen X. , Venkatramani Rajkumar , Bode Peter K. , Steinberg Seth M. , Zaki George , Kuznetsov Igor B. , Hawkins Douglas S. , Shern Jack F. , Collins Jack , Khan Javed
Published: April 2023

Supplemental Table S1. Whole slide image tissue segmentation statistics by an expert pathologist and probability prediction using a trained convolutional neural network. Supplemental Table S2. Clinical and molecular characteristics of FN-RMS samples used for training models for mutation prediction. Yellow boxes indicate genes included in defining the RAS pathway. Supplemental Table S3. Clinical information with COG risk stratification of FN-RMS samples used for training a prognostication predictive CNN.
Figure S6 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
Authors: Milewski David , Jung Hyun , Brown G. Thomas , Liu Yanling , Somerville Ben , Lisle Curtis , Ladanyi Marc , Rudzinski Erin R. , Choo-Wosoba Hyoyoung , Barkauskas Donald A. , Lo Tammy , Hall David , Linardic Corinne M. , Wei Jun S. , Chou Hsien-Chao , Skapek Stephen X. , Venkatramani Rajkumar , Bode Peter K. , Steinberg Seth M. , Zaki George , Kuznetsov Igor B. , Hawkins Douglas S. , Shern Jack F. , Collins Jack , Khan Javed
Published: April 2023

Supplemental Figure S6. Graphical User Interface for tissue segmentation, MYOD1 mutation prediction, and risk prediction models.
Figure S5 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
Authors: Milewski David , Jung Hyun , Brown G. Thomas , Liu Yanling , Somerville Ben , Lisle Curtis , Ladanyi Marc , Rudzinski Erin R. , Choo-Wosoba Hyoyoung , Barkauskas Donald A. , Lo Tammy , Hall David , Linardic Corinne M. , Wei Jun S. , Chou Hsien-Chao , Skapek Stephen X. , Venkatramani Rajkumar , Bode Peter K. , Steinberg Seth M. , Zaki George , Kuznetsov Igor B. , Hawkins Douglas S. , Shern Jack F. , Collins Jack , Khan Javed
Published: April 2023

Supplemental Figure S5. Frequency of mutations in COG and A.I. designated risk groups.
Figure S4 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
Authors: Milewski David , Jung Hyun , Brown G. Thomas , Liu Yanling , Somerville Ben , Lisle Curtis , Ladanyi Marc , Rudzinski Erin R. , Choo-Wosoba Hyoyoung , Barkauskas Donald A. , Lo Tammy , Hall David , Linardic Corinne M. , Wei Jun S. , Chou Hsien-Chao , Skapek Stephen X. , Venkatramani Rajkumar , Bode Peter K. , Steinberg Seth M. , Zaki George , Kuznetsov Igor B. , Hawkins Douglas S. , Shern Jack F. , Collins Jack , Khan Javed
Published: April 2023

Supplemental Figure S4. Sample partitioning for training a MYOD1 mutation predictive model using K-fold cross-validation.
Figure S2 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
Authors: Milewski David , Jung Hyun , Brown G. Thomas , Liu Yanling , Somerville Ben , Lisle Curtis , Ladanyi Marc , Rudzinski Erin R. , Choo-Wosoba Hyoyoung , Barkauskas Donald A. , Lo Tammy , Hall David , Linardic Corinne M. , Wei Jun S. , Chou Hsien-Chao , Skapek Stephen X. , Venkatramani Rajkumar , Bode Peter K. , Steinberg Seth M. , Zaki George , Kuznetsov Igor B. , Hawkins Douglas S. , Shern Jack F. , Collins Jack , Khan Javed
Published: April 2023

Supplemental Figure S2. Sample partitioning for training and testing a TP53 mutation predictive model using K-fold cross-validation.
Supplementary Tables1 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
Authors: Gopal Priyanka , Yard Brian D. , Petty Aaron , Lal Jessica C. , Bera Titas K. , Hoang Trung Q. , Buhimschi Alexandru D. , Abazeed Mohamed E.
Published: April 2023

Supplementary Tables
Supplementary Figures1 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
Authors: Gopal Priyanka , Yard Brian D. , Petty Aaron , Lal Jessica C. , Bera Titas K. , Hoang Trung Q. , Buhimschi Alexandru D. , Abazeed Mohamed E.
Published: April 2023

Supplementary Figures
Supplementary Data 6 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
Authors: Gopal Priyanka , Yard Brian D. , Petty Aaron , Lal Jessica C. , Bera Titas K. , Hoang Trung Q. , Buhimschi Alexandru D. , Abazeed Mohamed E.
Published: April 2023

Supplementary Data 6: Association between individual metabolites and radiation survival
Supplementary Data 5 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
Authors: Gopal Priyanka , Yard Brian D. , Petty Aaron , Lal Jessica C. , Bera Titas K. , Hoang Trung Q. , Buhimschi Alexandru D. , Abazeed Mohamed E.
Published: April 2023

Supplementary Data 5: Association between individual gene expression and radiation survival
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Authors: Termini Rosalinda , Žihala David , Terpos Evangelos , Perez-Montaña Albert , Jelínek Tomáš , Raab Marc , Weinhold Niels , Mai Elias K. , Grab Anna Luise , Corre Jill , Vergez Francois , Sacco Antonio , Chiarini Marco , Giustini Viviana , Tucci Alessandra , Rodriguez Sara , Moreno Cristina , Perez Cristina , Maia Catarina , Martín-Sánchez Esperanza , Guerrero Camilla , Botta Cirino , Garces Juan-Jose , Lopez Aitziber , Tamariz-Amador Luis-Esteban , Prosper Felipe , Bargay Joan , Cabezudo Maria-Elena , Ocio Enrique M. , Hájek Roman , Martinez-Lopez Joaquin , Solano Fernando , Iglesias Rebeca , Paiva Artur , Geraldes Catarina , Vitoria Helena , Gomez Clara , De Arriba Felipe , Ludwig Heinz , Garcia-Guiñon Antoni , Casanova Maria , Alegre Adrian , Cabañas Valentin , Sirvent Maialen , Oriol Albert , de la Rubia Javier , Hernández-Rivas José-Ángel , Palomera Luis , Sarasa Maria , Rios Pablo , Puig Noemi , Mateos Maria-Victoria , Flores-Montero Juan , Orfao Alberto , Goldschmidt Hartmut , Avet-Loiseau Hervé , Roccaro Aldo M. , San-Miguel Jesus F. , Paiva Bruno
Published: April 2023

Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Supplementary Figure from Phase I Trial of a Novel Anti-HER2 Antibody–Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer
Authors: Zhang Jian , Ji Dongmei , Shen Weina , Xiao Qin , Gu Yajia , O'Shaughnessy Joyce , Hu Xichun
Published: April 2023

Supplementary Figure from Phase I Trial of a Novel Anti-HER2 Antibody–Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer
Supplementary Data from Phase I Trial of a Novel Anti-HER2 Antibody–Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer
Authors: Zhang Jian , Ji Dongmei , Shen Weina , Xiao Qin , Gu Yajia , O'Shaughnessy Joyce , Hu Xichun
Published: April 2023

Supplementary Data from Phase I Trial of a Novel Anti-HER2 Antibody–Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer
Supplementary Data from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Authors: Termini Rosalinda , Žihala David , Terpos Evangelos , Perez-Montaña Albert , Jelínek Tomáš , Raab Marc , Weinhold Niels , Mai Elias K. , Grab Anna Luise , Corre Jill , Vergez Francois , Sacco Antonio , Chiarini Marco , Giustini Viviana , Tucci Alessandra , Rodriguez Sara , Moreno Cristina , Perez Cristina , Maia Catarina , Martín-Sánchez Esperanza , Guerrero Camilla , Botta Cirino , Garces Juan-Jose , Lopez Aitziber , Tamariz-Amador Luis-Esteban , Prosper Felipe , Bargay Joan , Cabezudo Maria-Elena , Ocio Enrique M. , Hájek Roman , Martinez-Lopez Joaquin , Solano Fernando , Iglesias Rebeca , Paiva Artur , Geraldes Catarina , Vitoria Helena , Gomez Clara , De Arriba Felipe , Ludwig Heinz , Garcia-Guiñon Antoni , Casanova Maria , Alegre Adrian , Cabañas Valentin , Sirvent Maialen , Oriol Albert , de la Rubia Javier , Hernández-Rivas José-Ángel , Palomera Luis , Sarasa Maria , Rios Pablo , Puig Noemi , Mateos Maria-Victoria , Flores-Montero Juan , Orfao Alberto , Goldschmidt Hartmut , Avet-Loiseau Hervé , Roccaro Aldo M. , San-Miguel Jesus F. , Paiva Bruno
Published: April 2023

Supplementary Data from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Supplementary Data 3 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Authors: Giraldo Nicolas A. , Drill Esther , Satravada Baby A. , Dika Imane El , Brannon A. Rose , Dermawan Josephine , Mohanty Abhinita , Ozcan Kerem , Chakravarty Debyani , Benayed Ryma , Vakiani Efsevia , Abou-Alfa Ghassan K. , Kundra Ritika , Schultz Nikolaus , Li Bob T. , Berger Michael F. , Harding James J. , Ladanyi Marc , O'Reilly Eileen M. , Jarnagin William , Vanderbilt Chad , Basturk Olca , Arcila Maria E.
Published: April 2023

Table S3. Therapy regimens
Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Authors: Oh Seung Yeon , Lee You Won , Lee Eun Ji , Kim Jae Hwan , Park YoungJoon , Heo Seong Gu , Yu Mi Ra , Hong Min Hee , DaSilva John , Daly Christopher , Cho Byoung Chul , Lim Sun Min , Yun Mi Ran
Published: April 2023

(A-C) The treatment history of each preclinical model patient was expressed in a bar model. Immunohistochemical evaluation of YHIM1035, YHIM1042 and YHIM1061 tumor sections using p-MET (3077), MET (8198), Ki67 (9027) antibody. and tumor volumes were measured once every 3 days.
Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Authors: Oh Seung Yeon , Lee You Won , Lee Eun Ji , Kim Jae Hwan , Park YoungJoon , Heo Seong Gu , Yu Mi Ra , Hong Min Hee , DaSilva John , Daly Christopher , Cho Byoung Chul , Lim Sun Min , Yun Mi Ran
Published: April 2023

The REGN5093-M114, Control Ab-M114 or osimertinib were treated with serial concentration. Cells were seeded on a 96-well plate and incubated, Cell viability was analyzed via CellTiter-Glo. The curve graph represents the viability for a single drug, and the bar graph shows the viability for two drugs.
Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Authors: Vaishampayan Ulka N. , Thakur Archana , Chen Wei , Deol Abhinav , Patel Meera , Dobson Kimberlee , Dickow Brenda , Schalk Dana , Schienschang Amy , Whitaker Sarah , Polend Amanda , Fontana Joseph A. , Heath Elisabeth I. , Lum Lawrence G.
Published: April 2023

A-C. FFPE sections of PC were stained by multiplex staining panel for CD4, CD8, FoxP3 (T regulatory cells), CD19 (B cells), CD68 (macrophages). Stained sections were imaged on the Hamamatsu slide scanner NanoZoomer S360 and images were viewed on the NDP viewer software. Analysis of images were performed on online Visiopharm software. Using the low power image, high-powered Fields (HPFs) were selected from specific tumor regions. Data shows the distribution of CD4+ (teal), CD8+ (purple), FoxP3 (brown), CD19+ (green) and CD68+ (yellow) cells on two representative whole scanned slide images (KCI 04 and KCI 11) are shown. Top panel shows whole scanned tumor sections, inset 1 and 2 are shown below at high magnification (40x). B and C) Show the second set of serial sections of tumor specimens stained for IFN-γ and IL-10 from two patients shown in the upper panel, both IFN-γ (brown) and IL-10 (brown) were stained individually.
Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Authors: Vaishampayan Ulka N. , Thakur Archana , Chen Wei , Deol Abhinav , Patel Meera , Dobson Kimberlee , Dickow Brenda , Schalk Dana , Schienschang Amy , Whitaker Sarah , Polend Amanda , Fontana Joseph A. , Heath Elisabeth I. , Lum Lawrence G.
Published: April 2023

A and B. Evaluation of Vβ repertoire. The three distinct patterns were observed for Vβ repertoire in CD3+/IFN-γ+ T cells post IT. Pattern 1) the proportions of Vβ repertoire noticeably higher after IT relative to preIT PBMC (solid black arrows); Pattern 2) the proportions of Vβ repertoire that were marginally higher at mid- and/or post-IT relative to pre-IT PBMC (dashed black arrows); Pattern 3) large proportions of Vβ repertoire were either lower or similar at mid-IT or post-IT relative to preIT PBMC in all four patients tested. PreIT (pretherapy), midIT (preinfusion 5) postIT (1 week post infusion 8 of BATs).
Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Authors: Oh Seung Yeon , Lee You Won , Lee Eun Ji , Kim Jae Hwan , Park YoungJoon , Heo Seong Gu , Yu Mi Ra , Hong Min Hee , DaSilva John , Daly Christopher , Cho Byoung Chul , Lim Sun Min , Yun Mi Ran
Published: April 2023

Cells were seeded on a 96-well plate and incubated with the REGN5093-M114, Control Ab-M114, and EGFR TKIs (osimertinib, lazertinib). Cell viability was measured after 5 days of REGN5093-M114 treatment and 3 days of capmatinib treatment via CellTiter-Glo. The curved graphs show the cell viability results for a single drug, and the bar-graphs show the cell viability for the combination of two drugs.
Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Authors: Oh Seung Yeon , Lee You Won , Lee Eun Ji , Kim Jae Hwan , Park YoungJoon , Heo Seong Gu , Yu Mi Ra , Hong Min Hee , DaSilva John , Daly Christopher , Cho Byoung Chul , Lim Sun Min , Yun Mi Ran
Published: April 2023

(A-B) Each cell viability was measured after treatment with REGN 5093-M114 for 5 days, capmatinib and tepotinib for 3 days. REGN 5093-M114 was treated with concentration of 0 µg/ml, 0.03 µg/ml, 0.1 µg/ml, 0.3 µg/ml, 1 µg/ml, 3 µg/ml. MET TKIs, capmatinib and tepotinib were treated with serial concentrations from 0nM to 100nM.
Supplementary Table S2 from Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma
Authors: Wang Jun , Guo Wei , Wang Xiaofang , Tang Xiaodong , Sun Xin , Ren Tingting
Published: April 2023

Correlation between Sr-exosomal PD-L1 detection by immunogold labeling and clinical features in patients with osteosarcoma
Supplementary Table S1 from Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma
Authors: Wang Jun , Guo Wei , Wang Xiaofang , Tang Xiaodong , Sun Xin , Ren Tingting
Published: April 2023

Characteristics of 67 patients with osteosarcoma
Supplementary Figures S1-S3 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
Authors: Ged Yasser , Sanchez Alejandro , Patil Sujata , Knezevic Andrea , Stein Emily , Petruzella Stacey , Weiss Kate , Duzgol Cihan , Chaim Joshua , Akin Oguz , Mourtzakis Marina , Paris Michael T. , Scott Jessica , Kuo Fengshen , Kotecha Ritesh , Hakimi A. Ari , Lee Chung-Han , Motzer Robert J. , Voss Martin H. , Furberg Helena
Published: April 2023

Associations of Body Composition and PFS
Supplementary Figure from Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
Authors: Lim Emerson A. , Bendell Johanna C. , Falchook Gerald S. , Bauer Todd M. , Drake Charles G. , Choe Jennifer H. , George Daniel J. , Karlix Janet L. , Ulahannan Susanna , Sachsenmeier Kris F. , Russell Deanna L. , Moorthy Ganesh , Sidders Ben S. , Pilling Elizabeth A. , Chen Huifang , Hattersley Maureen M. , Das Mayukh , Kumar Rakesh , Pouliot Gayle P. , Patel Manish R.
Published: April 2023

Supplementary Figure from Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
Supplementary Table from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Authors: Sun Kai , Xu Yitian , Zhang Licheng , Niravath Polly , Darcourt Jorge , Patel Tejal , Teh Bin S. , Farach Andrew M. , Guerrero Carlo , Mathur Sunil , Sultenfuss Mark A. , Gupta Nakul , Schwartz Mary R. , Haley Susan L. , Nair Sindhu , Li Xiaoxian , Nguyen Thi Truc Anh , Butner Joseph D. , Ensor Joe , Mejia Jaime A. , Mei Zhuyong , Butler E. Brian , Chen Shu-hsia , Bernicker Eric H. , Chang Jenny C.
Published: April 2023

Supplementary Table from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Authors: Chen Tom Wei-Wu , Hsu Chia-Lang , Hong Ruey-Long , Lee Jen-Chieh , Chang Koping , Yu Chih-Wei , Chen San-Chi , Guo Jhe-Cyuan , Chen Mei-Lu , Hsu Meng-Chi , Kung Ting-Fang , Cheng Ann-Lii , Yen Chueh-Chuan
Published: April 2023

Changes of cell types based on (a) MCP-Counter and (b) Danaher module with post- vs pre-treatment samples. All tests were performed by non-parametric Wilcoxon test.
Supplementary Figure from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Authors: Sun Kai , Xu Yitian , Zhang Licheng , Niravath Polly , Darcourt Jorge , Patel Tejal , Teh Bin S. , Farach Andrew M. , Guerrero Carlo , Mathur Sunil , Sultenfuss Mark A. , Gupta Nakul , Schwartz Mary R. , Haley Susan L. , Nair Sindhu , Li Xiaoxian , Nguyen Thi Truc Anh , Butner Joseph D. , Ensor Joe , Mejia Jaime A. , Mei Zhuyong , Butler E. Brian , Chen Shu-hsia , Bernicker Eric H. , Chang Jenny C.
Published: April 2023

Supplementary Figure from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Supplementary Appendix from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Authors: Chen Tom Wei-Wu , Hsu Chia-Lang , Hong Ruey-Long , Lee Jen-Chieh , Chang Koping , Yu Chih-Wei , Chen San-Chi , Guo Jhe-Cyuan , Chen Mei-Lu , Hsu Meng-Chi , Kung Ting-Fang , Cheng Ann-Lii , Yen Chueh-Chuan
Published: April 2023

Decision on Final Phase II dose; Guidelines combination dose level adjustments in the phase Ib phase; Schema for dose adjustments if more than 2 patients have DLT; Definitions of DLT
Supplementary Figure S6 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Authors: Mishra Akhilesh , Kumar Dhiraj , Gupta Kuldeep , Lofland Gabriela , Sharma Ajay Kumar , Banka Dhanush S. , Hobbs Robert F. , Dannals Robert F. , Rowe Steven P. , Gabrielson Edward , Nimmagadda Sridhar
Published: April 2023

[68Ga]Ga-DK223 PET reveals differential activity of PD-L1 antibodies over time in BFTC909 xenografts.
Supplementary Figure S2 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Authors: Mishra Akhilesh , Kumar Dhiraj , Gupta Kuldeep , Lofland Gabriela , Sharma Ajay Kumar , Banka Dhanush S. , Hobbs Robert F. , Dannals Robert F. , Rowe Steven P. , Gabrielson Edward , Nimmagadda Sridhar
Published: April 2023

A, Comparison of DOTA and DOTAGA analogs of DK221.
Supplementary Figure from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Authors: Constantinidou Anastasia , Marcou Yiola , Toss Michael S. , Simmons Timothy , Bernhisel Ryan , Hughes Elisha , Probst Braden , Meek Stephanie , Kakouri Eleni , Georgiou Georgios , Zouvani Ioanna , Savvidou Gabriella , Kuhl Vanessa , Doedt Jennifer , Wagner Susanne , Gutin Alexander , Slavin Thomas P. , Lanchbury Jerry S. , Kronenwett Ralf , Ellis Ian O. , Rakha Emad A.
Published: April 2023

Supplementary Figure from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Supplementary Figures S1-S17 from Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance
Authors: Carney Stephen V. , Banerjee Kaushik , Mujeeb Anzar , Zhu Brandon , Haase Santiago , Varela Maria L. , Kadiyala Padma , Tronrud Claire E. , Zhu Ziwen , Mukherji Devarshi , Gorla Preethi , Sun Yilun , Tagett Rebecca , Núñez Felipe J. , Luo Maowu , Luo Weibo , Ljungman Mats , Liu Yayuan , Xia Ziyun , Schwendeman Anna , Qin Tingting , Sartor Maureen A. , Costello Joseph F. , Cahill Daniel P. , Lowenstein Pedro R. , Castro Maria G.
Published: April 2023

Supplementary Figures and Figure Legends
Supplementary Table S2 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
Authors: Zhou Yan , Yang Qingcheng , Dong Yang , Ji Tong , Zhang Bing , Yang Cheng , Zheng Shuier , Tang Lina , Zhou Chenliang , Qian Guowei , Huang Yujing , Yu Wenxi , Li Hongtao , Wang Yonggang , He Aina , Shen Zan , Bao Qiyuan , Hua Yingqi , Bai Hongyu , Zhao Jiayi , Li Xiaoyi , Dai Xiangrong , Zhang Jianjun , Hu Haiyan , Yao Yang
Published: April 2023

ZKAB001 related TRAE That Occurred in all treated Patient Population
Supplementary Figure S4 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
Authors: Janssens Katleen , Vanhoutte Greetje , Lybaert Willem , Demey Wim , Decaestecker Jochen , Hendrickx Koen , Rezaei Kalantari Hassan , Zwaenepoel Karen , Pauwels Patrick , Fransen Erik , Op de Beeck Ken , Van Camp Guy , Rolfo Christian , Peeters Marc
Published: April 2023

Median methylation ratio.
Supplementary Figure S2 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
Authors: Janssens Katleen , Vanhoutte Greetje , Lybaert Willem , Demey Wim , Decaestecker Jochen , Hendrickx Koen , Rezaei Kalantari Hassan , Zwaenepoel Karen , Pauwels Patrick , Fransen Erik , Op de Beeck Ken , Van Camp Guy , Rolfo Christian , Peeters Marc
Published: April 2023

Kaplan Meier curve for progression free survival.
Supplementary Figure S1 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
Authors: Janssens Katleen , Vanhoutte Greetje , Lybaert Willem , Demey Wim , Decaestecker Jochen , Hendrickx Koen , Rezaei Kalantari Hassan , Zwaenepoel Karen , Pauwels Patrick , Fransen Erik , Op de Beeck Ken , Van Camp Guy , Rolfo Christian , Peeters Marc
Published: April 2023

Consort diagram.
Supplementary Figure 9 from Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
Authors: Rugo Hope S. , Raskina Kira , Schrock Alexa B. , Madison Russell W. , Graf Ryon P. , Sokol Ethan S. , Sivakumar Smruthy , Lee Jessica K. , Fisher Virginia , Oxnard Geoffrey R. , Tukachinsky Hanna
Published: April 2023

Supplementary Figure 9. Progression-free survival (PFS) among patients with SOLAR1mtreated with alpelisib+fulvestrant versus fulvestrant monotherapy.
Supplementary Figure 8 from Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
Authors: Rugo Hope S. , Raskina Kira , Schrock Alexa B. , Madison Russell W. , Graf Ryon P. , Sokol Ethan S. , Sivakumar Smruthy , Lee Jessica K. , Fisher Virginia , Oxnard Geoffrey R. , Tukachinsky Hanna
Published: April 2023

Supplementary Figure 8. Overall survival among patients with PIK3CA-mutatedHR+HER2- breast cancer treated with alpelisib/fulvestrant versus fulvestrant alone.
Supplementary Figure 1 from Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
Authors: Rugo Hope S. , Raskina Kira , Schrock Alexa B. , Madison Russell W. , Graf Ryon P. , Sokol Ethan S. , Sivakumar Smruthy , Lee Jessica K. , Fisher Virginia , Oxnard Geoffrey R. , Tukachinsky Hanna
Published: April 2023

Supplementary Figure 1. CONSORT diagram of genomic analyses cohorts
Figure S3 from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Authors: Debie Yana , Van Audenaerde Jonas R.M. , Vandamme Timon , Croes Lieselot , Teuwen Laure-Anne , Verbruggen Lise , Vanhoutte Greetje , Marcq Elly , Verheggen Lisa , Le Blon Debbie , Peeters Bart , Goossens Maria E. , Pannus Pieter , Ariën Kevin K. , Anguille Sébastien , Janssens Annelies , Prenen Hans , Smits Evelien L.J. , Vulsteke Christof , Lion Eva , Peeters Marc , van Dam Peter A.
Published: April 2023

Supplementary Figure 3: Gating strategy for a representative sample
Supplementary Table S6 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Authors: Visvanathan Kala , Cope Leslie , Fackler Mary Jo , Considine Michael , Sokoll Lori , Carey Lisa A. , Forero-Torres Andres , Ingle James N. , Lin Nancy U. , Nanda Rita , Storniolo Anna Maria , Tulac Suzana , Venkatesan Neesha , Wu Natalie C. , Marla Sudhakar , Campbell Scott , Bates Michael , Umbricht Christopher B. , Wolff Antonio C. , Sukumar Saraswati
Published: April 2023

Association between week 4 CM and disease status at first restaging after adjusting for CA27-29.
Supplementary Table S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Authors: Visvanathan Kala , Cope Leslie , Fackler Mary Jo , Considine Michael , Sokoll Lori , Carey Lisa A. , Forero-Torres Andres , Ingle James N. , Lin Nancy U. , Nanda Rita , Storniolo Anna Maria , Tulac Suzana , Venkatesan Neesha , Wu Natalie C. , Marla Sudhakar , Campbell Scott , Bates Michael , Umbricht Christopher B. , Wolff Antonio C. , Sukumar Saraswati
Published: April 2023

Association between week 4 CM and disease status at first restaging after adjusting for CEA.
Supplementary table 7 from Single-Cell Transcriptomics Reveals Immune Reconstitution in R/R T-ALL/LBL Patients with Donor-Derived CD7 CAR-T Therapy
Authors: Chen Wei , Shi Hui , Liu Zhuojun , Yang Fan , Liu Jia , Zhang Leqiang , Wu Yajin , Xia Yuanshi , Ou Yuxuan , Li Ruiting , Zhang Ting , Zhang Jiecheng , Ke Xiaoyan , Hu Kai , Yu Jian
Published: April 2023

Supplementary table 7
Supplementary table 6 from Single-Cell Transcriptomics Reveals Immune Reconstitution in R/R T-ALL/LBL Patients with Donor-Derived CD7 CAR-T Therapy
Authors: Chen Wei , Shi Hui , Liu Zhuojun , Yang Fan , Liu Jia , Zhang Leqiang , Wu Yajin , Xia Yuanshi , Ou Yuxuan , Li Ruiting , Zhang Ting , Zhang Jiecheng , Ke Xiaoyan , Hu Kai , Yu Jian
Published: April 2023

Supplementary table 6
Supplementary materials and methods 1 from Single-Cell Transcriptomics Reveals Immune Reconstitution in R/R T-ALL/LBL Patients with Donor-Derived CD7 CAR-T Therapy
Authors: Chen Wei , Shi Hui , Liu Zhuojun , Yang Fan , Liu Jia , Zhang Leqiang , Wu Yajin , Xia Yuanshi , Ou Yuxuan , Li Ruiting , Zhang Ting , Zhang Jiecheng , Ke Xiaoyan , Hu Kai , Yu Jian
Published: April 2023

Supplementary materials and methods
Supplementary figures 1-4 from Single-Cell Transcriptomics Reveals Immune Reconstitution in R/R T-ALL/LBL Patients with Donor-Derived CD7 CAR-T Therapy
Authors: Chen Wei , Shi Hui , Liu Zhuojun , Yang Fan , Liu Jia , Zhang Leqiang , Wu Yajin , Xia Yuanshi , Ou Yuxuan , Li Ruiting , Zhang Ting , Zhang Jiecheng , Ke Xiaoyan , Hu Kai , Yu Jian
Published: April 2023

Supplementary figure 1-4
Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Authors: Visvanathan Kala , Cope Leslie , Fackler Mary Jo , Considine Michael , Sokoll Lori , Carey Lisa A. , Forero-Torres Andres , Ingle James N. , Lin Nancy U. , Nanda Rita , Storniolo Anna Maria , Tulac Suzana , Venkatesan Neesha , Wu Natalie C. , Marla Sudhakar , Campbell Scott , Bates Michael , Umbricht Christopher B. , Wolff Antonio C. , Sukumar Saraswati
Published: April 2023

Supplementary figure 4 displays time updates ROC curves for week 4 CM level using two additional methods (A) binary thresholding and (B) random forest.
Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Authors: Visvanathan Kala , Cope Leslie , Fackler Mary Jo , Considine Michael , Sokoll Lori , Carey Lisa A. , Forero-Torres Andres , Ingle James N. , Lin Nancy U. , Nanda Rita , Storniolo Anna Maria , Tulac Suzana , Venkatesan Neesha , Wu Natalie C. , Marla Sudhakar , Campbell Scott , Bates Michael , Umbricht Christopher B. , Wolff Antonio C. , Sukumar Saraswati
Published: April 2023

Supplementary Figure 3 displays baseline CM level by disease status at first restaging.
Supplementary Tables S1-S3 from A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
Authors: Yap Timothy A. , LoRusso Patricia M. , Wong Deborah J. , Hu-Lieskovan Siwen , Papadopoulos Kyriakos P. , Holz Josefin-Beate , Grabowska Urszula , Gradinaru Cristian , Leung Kin-Mei , Marshall Sylwia , Reader Claire S. , Russell Roslin , Sainson Richard C.A. , Seal Claire J. , Shepherd Christopher J. , Germaschewski Fiona , Gliddon Daniel , Stern Omer , Young Lesley , Brewis Neil , Kayitalire Louis , Morrow Michelle
Published: April 2023

Supplementary Table S1: Representativeness of Study Participants.Supplementary Table S2: Immunogenicity in patients treated with FS118.Supplementary Table S3: PK of FS118 by Dose Level.
Supplementary Figures S1-S4 from ACTA2 Expression Predicts Survival and Is Associated with Response to Immune Checkpoint Inhibitors in Gastric Cancer
Authors: Park Sunho , Karalis John D. , Hong Changjin , Clemenceau Jean R. , Porembka Matthew R. , Kim In-Ho , Lee Sung Hak , Wang Sam C. , Cheong Jae-Ho , Hwang Tae Hyun
Published: April 2023

Supplementary Figure 1. ACTA2 expression was elevated in the molecular subtype with the worst prognosis (Group 4). Supplementary Figure 2. ACTA2 expression stratified by microsatellite stability status in the pooled cohort. Supplementary Figure 3. Alternatively tested thresholds to stratify patients into ACTA2-High and ACTA2-Low groups.Supplementary Figure 4. ACTA2 expression stratified by microsatellite stability status in the immune checkpoint inhibitor cohort.
Supplemental Figure 2 from Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells
Authors: Rotolo Ramona , Leuci Valeria , Donini Chiara , Galvagno Federica , Massa Annamaria , De Santis Maria Chiara , Peirone Serena , Medico Giovanni , Sanlorenzo Martina , Vujic Igor , Gammaitoni Loretta , Basiricò Marco , Righi Luisella , Riganti Chiara , Salaroglio Iris Chiara , Napoli Francesca , Tabbò Fabrizio , Mariniello Annapaola , Vigna Elisa , Modica Chiara , D’Ambrosio Lorenzo , Grignani Giovanni , Taulli Riccardo , Hirsch Emilio , Cereda Matteo , Aglietta Massimo , Scagliotti Giorgio Vittorio , Novello Silvia , Bironzo Paolo , Sangiolo Dario
Published: April 2023

Treatment with PD-L1s is associated with the up-regulation of expression of key protein coding genes involved in processes of tumorigenesis, EMT, tumor aggressiveness and chemoresistance.
Heatmap showing z-scaled DESeq2-normalized expression values of the 14 differentially expressed genes between PD-L1s and untreated cells. Right annotation indicates the mean DESeq2-normalized gene expression values. Top annotations depict the pneumosphere of origin and the treatment. Hierarchical clustering of genes and samples is shown on the left and top, respectively (A). Volcano plot showing the log2 fold change (log2FC) and adjusted p-value values of all genes between PD-L1s and untreated samples. Differentially expressed genes are depicted in red (B).
Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Authors: Chen Evan C. , Gandler Helen , Tošić Isidora , Fell Geoffrey G. , Fiore Ashlee , Pozdnyakova Olga , DeAngelo Daniel J. , Galinsky Ilene , Luskin Marlise R. , Wadleigh Martha , Winer Eric S. , Leonard Rebecca , O'Day Kelsey , de Jonge Adrienne , Neuberg Donna , Look A. Thomas , Stone Richard M. , Frank David A. , Garcia Jacqueline S.
Published: April 2023

Survival outcomes for the overall cohort. A, Progression-free survival. B, Overall survival.
Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Authors: Chen Evan C. , Gandler Helen , Tošić Isidora , Fell Geoffrey G. , Fiore Ashlee , Pozdnyakova Olga , DeAngelo Daniel J. , Galinsky Ilene , Luskin Marlise R. , Wadleigh Martha , Winer Eric S. , Leonard Rebecca , O'Day Kelsey , de Jonge Adrienne , Neuberg Donna , Look A. Thomas , Stone Richard M. , Frank David A. , Garcia Jacqueline S.
Published: April 2023

Co-mutation profiles of study subjects. Ordered by frequency. Presence of complex and/or monosomal karyotypes are also denoted in bottom rows.
Supplementary Figure S2 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations
Authors: Sivakumar Smruthy , Jin Dexter X. , Rathod Ruchita , Ross Jeffrey , Cantley Lewis C. , Scaltriti Maurizio , Chen Jessica W. , Hutchinson Katherine E. , Wilson Timothy R. , Sokol Ethan S. , Vasan Neil
Published: April 2023

Breakdown of the different tumor types among double-PIK3CA mutant samples based on their clonality and cis/trans status.
Supplementary Table S2 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Authors: Cheema Amrita K. , Li Yaoxiang , Ventimiglia Mary , Kowalczyk Keith , Hankins Ryan , Bandi Gaurav , Janowski Einsley-Marie , Grindrod Scott , Villagra Alejandro , Dritschilo Anatoly
Published: April 2023

Reactome based longitudinal pathway analysis showing significantly dysregulated pathways at 1 h, 24 hours, 1-, 3-, 6-, and 12-months following RT in the GU prostate cancer cohort.
Supplementary Table S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Authors: Doe-Tetteh Seyram A. , Camp Sabrina Y. , Reales Dalicia , Crowdis Jett , Noronha Anne Marie , Wolff Bernadette , Alano Tina , Galle Jesse , Selcuklu S. Duygu , Viale Agnes , Socci Nicholas D. , Liu Ying L. , Tew William P. , Aghajanian Carol , Ladanyi Marc , He Meng Xiao , AlDubayan Saud H. , Mazor Roei David , Shpilberg Ofer , Hershkovitz-Rokah Oshrat , Riancho Jose A. , Hernandez Jose L. , Gonzalez-Vela M. Carmen , Buthorn Justin J. , Wilson Manda , Webber Amy E. , Yabe Mariko , Petrova-Drus Kseniya , Rosenblum Marc , Durham Benjamin H. , Abdel-Wahab Omar , Berger Michael F. , Donoghue Mark T.A. , Kung Andrew L. , Glade Bender Julia , Shukla Neerav N. , Funt Samuel A. , Dogan Ahmet , Soslow Robert A. , Al-Ahmadie Hikmat , Feldman Darren R. , Van Allen Eliezer M. , Diamond Eli L. , Solit David B.
Published: April 2023

Genomically matched targeted therapies guided by MSK-IMPACT testing (n=22).
Supplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Authors: Doe-Tetteh Seyram A. , Camp Sabrina Y. , Reales Dalicia , Crowdis Jett , Noronha Anne Marie , Wolff Bernadette , Alano Tina , Galle Jesse , Selcuklu S. Duygu , Viale Agnes , Socci Nicholas D. , Liu Ying L. , Tew William P. , Aghajanian Carol , Ladanyi Marc , He Meng Xiao , AlDubayan Saud H. , Mazor Roei David , Shpilberg Ofer , Hershkovitz-Rokah Oshrat , Riancho Jose A. , Hernandez Jose L. , Gonzalez-Vela M. Carmen , Buthorn Justin J. , Wilson Manda , Webber Amy E. , Yabe Mariko , Petrova-Drus Kseniya , Rosenblum Marc , Durham Benjamin H. , Abdel-Wahab Omar , Berger Michael F. , Donoghue Mark T.A. , Kung Andrew L. , Glade Bender Julia , Shukla Neerav N. , Funt Samuel A. , Dogan Ahmet , Soslow Robert A. , Al-Ahmadie Hikmat , Feldman Darren R. , Van Allen Eliezer M. , Diamond Eli L. , Solit David B.
Published: April 2023

Clonality assessment of known oncogenic mutations in the female GCT cohort.
Supplementary Tables S1-4 from Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
Authors: Kinneer Krista , Wortmann Philipp , Cooper Zachary A. , Dickinson Niall J. , Masterson Luke , Cailleau Thais , Hutchinson Ian , Vijayakrishnan Balakumar , McFarlane Mary , Ball Kathryn , Davies Michael , Lewis Arthur , Huang Yue , Rosenbaum Anton I. , Yuan Jiaqi , Chesebrough Jon , Anderton Judith , Monks Noel , Novick Steven , Wang Jixin , Dimasi Nazzareno , Christie R. James , Sabol Darrin , Tosto Frances Anne , Wallez Yann , Leo Elisabetta , Albertella Mark R. , Staniszewska Anna D. , Tice David A. , Howard Philip W. , Luheshi Nadia , Sapra Puja
Published: April 2023

Supplementary Table S1. Primary antibodies used for immunoblotting; Supplementary Table S2. Characterization of ADCs evaluated in this study; Supplementary Table S3. B7-H4 expression in human normal tissue; Supplementary Table S4. Binding affinity of anti-B7-H4 antibody INT016 Fab to human, cynomolgus monkey, and mouse B7-H4, measured by surface plasmon resonance.
Supplementary Figures S11-18 from Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
Authors: Kinneer Krista , Wortmann Philipp , Cooper Zachary A. , Dickinson Niall J. , Masterson Luke , Cailleau Thais , Hutchinson Ian , Vijayakrishnan Balakumar , McFarlane Mary , Ball Kathryn , Davies Michael , Lewis Arthur , Huang Yue , Rosenbaum Anton I. , Yuan Jiaqi , Chesebrough Jon , Anderton Judith , Monks Noel , Novick Steven , Wang Jixin , Dimasi Nazzareno , Christie R. James , Sabol Darrin , Tosto Frances Anne , Wallez Yann , Leo Elisabetta , Albertella Mark R. , Staniszewska Anna D. , Tice David A. , Howard Philip W. , Luheshi Nadia , Sapra Puja
Published: April 2023

Supplementary Figure S11. In vitro cytotoxicity of the TOP1i warhead AZ’0132 to HT29 and HT29-huB7-H4 cells; Supplementary Figure S12. Study design for pharmacodynamic and pharmacokinetic analysis of AZD8205 in HT29 and HT29-huB7-H4 mouse xenograft models; Supplementary Figure S13. DNA damage response signaling in HT29-huB7-H4 and MX-1 cells treated with AZD8205 or the TOP1i warhead AZ’0132; Supplementary Figure S14. Accumulation of AZD8205 and changes in epithelial cell density in HT29 and HT29-huB7-H4 tumor xenografts over time; Supplementary Figure S15. Correlation of B7-H4 mean OD and gene expression in TNBC PDX models; Supplementary Figure S16. Impact of homologous recombination deficiency (HRD) on sensitivity to the TOP1i warhead AZ’0132 in vitro with SK-OV-3 ovarian cancer isogenic cells; Supplementary Figure S17. SLFN11 expression in PDX models; Supplementary Figure S18. Analysis of SLFN11 expression and AZD8205 response in PDX.
Supplementary Figures S1-10 from Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
Authors: Kinneer Krista , Wortmann Philipp , Cooper Zachary A. , Dickinson Niall J. , Masterson Luke , Cailleau Thais , Hutchinson Ian , Vijayakrishnan Balakumar , McFarlane Mary , Ball Kathryn , Davies Michael , Lewis Arthur , Huang Yue , Rosenbaum Anton I. , Yuan Jiaqi , Chesebrough Jon , Anderton Judith , Monks Noel , Novick Steven , Wang Jixin , Dimasi Nazzareno , Christie R. James , Sabol Darrin , Tosto Frances Anne , Wallez Yann , Leo Elisabetta , Albertella Mark R. , Staniszewska Anna D. , Tice David A. , Howard Philip W. , Luheshi Nadia , Sapra Puja
Published: April 2023

Supplementary Figure S1. Analytical characterization of INT016-ADCs; Supplementary Figure S2. Validation of B7-H4 antibodies for use in IHC; Supplementary Figure S3. Relationship between B7-H4 expression level and heterogeneity in the studied human triple-negative cohort; Supplementary Figure S4. Binding of antibody INT016 to HEK 293 cells stably expressing human, mouse, or cynomolgus monkey B7-H4; Supplementary Figure S5. Binding of antibody INT016 to human breast cancer cell lines and to HT29 cells stably expressing human B7-H4; Supplementary Figure S6. Internalization and lysosomal trafficking of INT016; Supplementary Figure S7. In vitro stability of INT016-ADCs in mouse and cynomolgus monkey serum; Supplementary Figure S8. In vitro cytotoxicity of INT016-ADCs in HT29 and HT29-huB7-H4 isogenic cell lines; Supplementary Figure S9. In vivo efficacy of INT016-ADCs in the MX-1 xenograft model; Supplementary Figure S10. Growth rate analysis of MX-1 in vivo efficacy study comparing INT016-ADCs from days 14–40.
Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Authors: Owen Dwight H. , Benner Brooke , Wei Lai , Sukrithan Vineeth , Goyal Ashima , Zhou Ye , Pilcher Carly , Suffren Sheryl-Ann , Christenson Gwen , Curtis Nancy , Jukich Megan , Schwarz Emily , Savardekar Himanshu , Norman Ruthann , Ferguson Sarah , Kleiber Barbara , Wesolowski Robert , Carson William E. , Otterson Gregory A. , Verschraegen Claire F. , Shah Manisha H. , Konda Bhavana
Published: April 2023

Evaluation of circulating MDSC. (A) Changes in total MDSC and (B) monocytic (M-MDSC) and granulocytic (G-MDSC) subsets at cycle 1, day 15 (C1D15) compared to screening in the entire patient cohort. (C) Levels of circulating MDSC at screening by clinical response and changes during study treatment compared to screening in partial response (PR, orange) and stable disease (SD, green) patients. Each symbol represents one patient (n = 9). Line indicates mean.
Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
Authors: van 't Erve Iris , Medina Jamie E. , Leal Alessandro , Papp Eniko , Phallen Jillian , Adleff Vilmos , Chiao Elaine Jiayuee , Arun Adith S. , Bolhuis Karen , Simmons John K. , Karandikar Aanavi , Valkenburg Kenneth C. , Sausen Mark , Angiuoli Samuel V. , Scharpf Robert B. , Punt Cornelis J.A. , Meijer Gerrit A. , Velculescu Victor E. , Fijneman Remond J.A.
Published: April 2023

The Supplementary Tables file consists of Supplementary Tables 1 to 15 belonging to the manuscript "Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells"
Supplementary Figure 3 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
Authors: Mondello Patrizia , Paludo Jonas , Novak Joseph P. , Wenzl Kerstin , Yang Zhi-Zhang , Jalali Shahrzad , Krull Jordan E. , Braggio Esteban , Dasari Surendra , Manske Michelle K. , Abeykoon Jithma A. , Sarangi Vivekananda , Kapoor Prashant , Paulus Aneel , Reeder Craig B. , Ailawadhi Sikander , Chanan-Khan Asher A. , Kyle Robert A. , Gertz Morie A. , Novak Anne J. , Ansell Stephen M.
Published: April 2023

Supplementary Figure 3 Boxplot showing that 6q deletion resulted in decreased expression of TNFAIP3.